Related Experiment Video
Updated: Oct 16, 2026
08:00
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
Published on: April 16, 2019
Temozolomide (Temodal) for treatment of primary brain tumours
Intensive & Critical Care Nursing
|May 3, 2000
Abstract:
Although the outlook for patients with malignant gliomas continues to be very poor, progress in neurosurgery and radiotherapy, supported by new development in chemotherapy, offer some hope for the future. Temozolomide has recently been introduced by Schering-Plough Ltd (Welwyn Garden City, UK) as a new treatment which merits further investigation in this situation.
Insights
Malignant glioma treatment remains challenging. New chemotherapy, temozolomide, shows promise and requires further investigation for improved patient outcomes.
Area of Science:
- Neuro-oncology
- Medical chemotherapy
- Malignant glioma research
Background:
- Malignant gliomas have a poor prognosis.
- Advances in neurosurgery and radiotherapy offer limited improvements.
- Chemotherapy represents a developing area of treatment.
Purpose of the Study:
- To introduce temozolomide as a novel chemotherapy agent.
- To highlight the need for further investigation of temozolomide.
- To provide a potential new avenue for malignant glioma treatment.
Main Methods:
- Investigational chemotherapy agent: temozolomide.
- Clinical context: treatment of malignant gliomas.
- Further research is indicated.
Main Results:
- Temozolomide is a new chemotherapy treatment.
- It offers potential hope for patients with malignant gliomas.
- Further investigation is warranted.
Conclusions:
- Despite poor outlook, progress in neurosurgery, radiotherapy, and chemotherapy offers hope.
- Temozolomide is a new chemotherapy agent requiring further study.
- This agent may improve outcomes for malignant glioma patients.
